Abstract
T-cell checkpoint inhibitors treat the cancer patient's immune system potentially inducing significant long-term survival. Pembrolizumab demonstrates clinical activity in patients diagnosed with melanoma and other cancers. Its mode of action suggests a rationale for combination with other treatment modalities, urging oncologists to brush up their knowledge of immunology.
©2015 American Association for Cancer Research.
MeSH terms
-
Antibodies, Monoclonal, Humanized / pharmacology*
-
Antibodies, Monoclonal, Humanized / therapeutic use*
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use*
-
Humans
-
Immunomodulation / drug effects
-
Molecular Targeted Therapy
-
Neoplasms / drug therapy*
-
Neoplasms / immunology*
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
T-Lymphocyte Subsets / drug effects
-
T-Lymphocyte Subsets / immunology
-
T-Lymphocyte Subsets / metabolism
-
Translational Research, Biomedical
Substances
-
Antibodies, Monoclonal, Humanized
-
Antineoplastic Agents
-
pembrolizumab